Full Text View
Tabular View
No Study Results Posted
Related Studies
Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer (TAPS)
This study is ongoing, but not recruiting participants.
Study NCT00298155   Information provided by University of Washington
First Received: February 27, 2006   Last Updated: January 27, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Prostate Neoplasms
Additional conditions recognized in this trial
Neoplasms
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
goserelin with dutasteride
Additional drug interventions recognized in this trial
Androgens
Bicalutamide
Dutasteride
Goserelin
Ketoconazole
More general drug interventions related to this trial
Androgen Antagonists
Anti-Infective Agents
Antifungal Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Enzyme Inhibitors
Hormone Antagonists
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of Washington
GlaxoSmithKline
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services